FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Buy Rating On Shares Of Illumina

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month price target to $161 from $140, 31x our 2026 EPS estimate (up to $5.18 from $5.13; 2027 estimate up to $5.89 from $5.81), a premium to ILMN's one-year historical forward average of 24x. We were encouraged by ex-China organic sales rising ~3.5% Y/Y in Q1, while adjusted operating margin rose 150 bps Y/Y to 21.9%. We look positively on recent Congressional action to modestly increase the National Institutes of Health (NIH) budget (~1%) rather than the dramatic cuts initially feared by investors, though ILMN's guidance implies continued pressure in academic end markets in 2026. Excluding China, sequencing consumables within research and applied was down 12% Y/Y in Q1, though clinical consumables sales rose 20% Y/Y. Positively, ILMN placed over 80 NovaSeq X instruments (up 20 Y/Y) during the quarter, indicating strong momentum.

Related Articles

Research

Research Alert: CFRA Lowers Opinion On Shares Of Quanta Services, Inc. To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target by $158 to $773, which is 52.6x our next-12-month EPS estimate of $14.70. We also lift our 2026 EPS by $0.93 to $14.31 and 2027's by $1.18 to $16.74. Our move to Hold partially reflects our difficulty in justifying valuation levels that could offer sufficient upside after surging 15.8% on Q1 results. Both sides of the valuation equation in our updated $773 target are considerably higher than those in our prior $615 target, which was calculated using a 46.0x multiple on $13.38 EPS. Even after increasing the multiple by 14.3% and EPS by 9.9%, we only see ~4% upside at current levels. While PWR's fundamentals remain strong with record backlog and solid execution, the risk/reward profile has shifted to neutral. This is due to mounting concerns around data center project delays/cancellations (industry estimates suggest 30%-50% of 2026 projects are at risk), increasing exposure to fixed-price contract cost overruns, and growing difficulty collecting disputed change orders from customers.

$PWR
Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Entergy Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target by $13 to $117, 26.0x our next-12-month EPS estimate of $4.49, a premium to its five-year forward average of 18x. We lift our 2026 EPS view by $0.01 to $4.40 and our 2027 EPS view by $0.07 to $4.95. ETR maintained its 2026 adjusted EPS guidance range of $4.25-$4.45 (midpoint of $4.35) and raised 2027-2029 guidance by $0.20-$0.50, with 2029 adjusted EPS now expected at $6.40. The company's enhanced earnings trajectory and substantial capital deployment position it well for sustained growth, in our view. Key execution items to monitor include regulatory approval of the Louisiana Lightning filing (expected December 2026), sourcing the remaining $4.7B in equity through 2029, and construction execution on seven new combined-cycle plants by 2030-2031. We anticipate dividend growth will remain competitive with peers (5.2% CAGR from 2025 to 2028), though we think recent share price and valuation advances have reduced near-term upside potential relative to peers.

$ETR
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 results, we up our target to $48 from $39, based on our NPV analysis. We widen our 2026 LPS view to -$7.95 from -$7.16 and keep our 2027 LPS view at -$4.82. MRNA reported a strong Q1, exceeding revenue expectations and demonstrating significant Y/Y growth. During the analyst call, management highlighted key regulatory approvals in Europe for its respiratory vaccine portfolio and oncology pipeline advancements, which we find encouraging. Despite a GAAP net loss widened by a one-time litigation settlement, underlying financial discipline and cost reduction efforts are noteworthy. Yet, revenue guidance for Q2 is relatively low at $50M-$100M (CFRA: $92M), which points to a 65%-30% Y/Y deceleration (CFRA: 35%) but also signals a significant swing Q/Q after the company recorded $153M in sales in Q1. While we think the progress in the oncology pipeline with the partnership with Merck & Co. (MRK 112 ****) is promising and progressing well, we continue to view MRNA as a wait and see story.

$MRNA